Pre-made Tarlatamab biosimilar ( Bispecific scFv, anti-DLL3;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-552
Anti-DLL3;CD3E therapeutic antibody (Pre-made Tarlatamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tarlatamab is a half-life extended delta-like protein 3 (DLL3)/anti-CD3 bispecific T-cell engager (HLE BiTE) antibody construct, being developed by Amgen for the treatment of small cell lung cancer, neuroendocrine prostate cancer and metastatic melanoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-DLL3;CD3E therapeutic antibody (Pre-made Tarlatamab biosimilar,Bispecific scFv)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Small cell lung cancer|
|Development Tech||BiTE Technology|